BRAF
BRAF is highly significantly mutated in melanoma.
BRAF encodes a serine/threonine protein kinase that regulates the MAP kinase/ERK signaling pathway. Mutations in BRAF are associated with several cancers, most notably melanoma, colorectal cancer, non‑small cell lung carcinoma, and other malignancies. The gene is highly and significantly mutated in melanoma, with approximately 63% of patients in the dataset harboring BRAF alterations.
BRAF mutations drive oncogenesis through constitutive activation of the MAPK pathway, making BRAF a key therapeutic target. Understanding the mutation spectrum and prevalence of BRAF across tumor types informs precision oncology strategies and the development of BRAF‑inhibitor therapies.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies